Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (84 day) for reimbursement as a treatment option for the maintenance treatment of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients who have responded to induction therapy.

This is written in the approval document as:

Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.

Citation

riTUXimab (S/C 1400mg) Maintenance Therapy-84 day, 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6401/599_v2a_riTUXimab_SC_1400mg_Therapy_every_three_months.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
HSE (1)	CD20 +	Follicular Lymphoma	Rituximab